Mercy BioAnalytics

About Mercy BioAnalytics

Mercy Bio is revolutionizing early-stage cancer detection through its innovative use of extracellular vesicles (EVs) found in blood. These EVs, which are shed by cells at a rate of 1,000 per cell per day, carry specific information about their parent cells, making them a powerful tool for identifying cancer at its earliest stages. The company's flagship product, the Mercy Halo test, is the first and only test that leverages this technology to provide precise, non-invasive diagnostics. Mercy Bio primarily serves healthcare providers and research institutions focused on oncology. Operating in the medical diagnostics market, the company follows a B2B (business-to-business) model, generating revenue through the sale of its diagnostic tests and related services. By making early-stage cancer detection 100,000 times easier, Mercy Bio aims to significantly reduce the costs and challenges associated with early cancer diagnosis, ultimately improving patient outcomes.